What is Agios Pharmaceuticals's return on equity?

Agios Pharmaceuticals (AGIO) reported return on equity of -32.8% in Q1 2026.

What is the long-term trend for Agios Pharmaceuticals's return on equity?

Over 3 years (2020 to 2025), Agios Pharmaceuticals's return on equity has grown at a -21.7% compound annual growth rate (CAGR), from -63% to -30.2%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Agios Pharmaceuticals AGIO Return on equity

Return on equity at other companies

Bristol-Myers SquibbBMY

38.8%+7.3pp

PfizerPFE

10.6%—

Vertex PharmaceuticalsVRTX

24.2%—

IncyteINCY

30.8%+30.4pp

BioMarin PharmaceuticalsBMRN

9.1%+2.8pp

Disc MedicineIRON

-35.8%+41.3pp

Other financials

Income statement

See full

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Balance sheet

See full

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Valuation

See full

Market cap$2.12B+18.1%

Enterprise value$2.04B+15.2%

P/S32.1×-16.4×

Profitability

See full

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Returns & leverage

See full

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Where this comes from

Calculated from Agios Pharmaceuticals’s reported figures.

net income/total stockholders equity=-32.8%

Based on trailing twelve months.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Agios Pharmaceuticals's return on equity?: Agios Pharmaceuticals (AGIO) reported return on equity of -32.8% in Q1 2026.
What is the long-term trend for Agios Pharmaceuticals's return on equity?: Over 3 years (2020 to 2025), Agios Pharmaceuticals's return on equity has grown at a -21.7% compound annual growth rate (CAGR), from -63% to -30.2%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.